Philip C. Johnson, MD; L. Joseph Wheat, MD; Gretchen A. Cloud, MS; Mitchell Goldman, MD; Dan Lancaster, MD; David M. Bamberger, MD; William G. Powderly, MD; Richard Hafner, MD; Carol A. Kauffman, MD; William E. Dismukes, MD; for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group*
Note: This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 31 January 2000.
Acknowledgments: The authors thank Deanne Fuller, Dr. Tom Davis, and Ann LeMonte for laboratory work; Estella C. Wheatley for preparation of the manuscript; and Cynthia R. Flanigan for help with the management of the data over the course of the clinical trial.
Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (contract NO1-A1-15802) and by a grant from the National Center for Research Resources, General Clinical Research Center (contract MO1-RR02558) to participating centers, and by Gilead Sciences, Inc. (formerly NeXstar Pharmaceuticals).
Requests for Single Reprints: Philip C. Johnson, MD, University of Texas–Houston Medical School, Division of General Medicine, 6431 Fannin, MSB 1.122, Houston, TX 77030; e-mail, Philip.C.Johnson@uth.tmc.edu.
Current Author Addresses: Dr. Johnson: Division of General Medicine, University of Texas–Houston Medical School, 6431 Fannin, MSB 1.122, Houston, TX 77030.
Dr. Wheat: Indiana University School of Medicine, OPW 430, 1001 West 10th Street, Indianapolis, IN 46202-2879.
Ms. Cloud: University of Alabama at Birmingham, Liberty National Building, LNB 1078, Suite 1078, 2001 Third Avenue South, Birmingham, AL 35233.
Dr. Goldman: Wishard Memorial Hospital, 430 OPW, 1001 West 10th Street, Indianapolis, IN 46202.
Dr. Lancaster: Methodist Hospital, One Tower 1265 Union Avenue, Memphis, TN 38104.
Dr. Bamberger: University of Missouri–Kansas City, School of Medicine, Division of Infectious Diseases, Red 4 Unit, 2411 Holmes Street, Kansas City, MO 64108-2792.
Dr. Powderly: Washington University School of Medicine, Division of Infectious Diseases, Campus Box 8051, 660 South Euclid, St. Louis, MO 63110.
Dr. Hafner: National Institute of Allergy and Infectious Diseases, Division of AIDS, National Institutes of Health, 6700-B Rockledge Drive, MSC 7624, Room 5107, Bethesda, MD 20817.
Dr. Kauffman: VA Medical Center, Infectious Diseases Section, 2215 Fuller Road, Ann Arbor, MI 48105.
Dr. Dismukes: University of Alabama School of Medicine at Birmingham, Department of Medicine and Division of Infectious Diseases, THT 229-1900 University Boulevard, Birmingham, AL 35294-0006.
Author Contributions: Conception and design: P.C. Johnson, L.J. Wheat, G.A. Cloud, B.M. Bamberger, W.G. Powderly, R. Hafner, C.A. Kauffman, W. Dismukes.
Analysis and interpretation of the data: P.C. Johnson, L.J. Wheat, G.A. Cloud, M. Goldman, D.M. Bamberger, W.G. Powderly, C.A. Kauffman, W.E. Dismukes.
Drafting of the article: P.C. Johnson, L.J. Wheat, G.A. Cloud, W. Dismukes.
Critical revision of the article for important intellectual content: P.C. Johnson, L.J. Wheat, G.A. Cloud, M. Goldman, D. Lancaster, D.M. Bamberger, W.G. Powderly, R. Hafner, C.A. Kauffman, W. Dismukes.
Final approval of the article: P.C. Johnson, L.J. Wheat, G.A. Cloud, M. Goldman, D. Lancaster, D.M. Bamberger, W.G. Powderly, R. Hafner, C.A. Kauffman, W. Dismukes.
Provision of study materials or patients: P.C. Johnson, L.J. Wheat, G.A. Cloud, M. Goldman, D. Lancaster, D.M. Bamberger, W.G. Powderly.
Statistical expertise: G.A. Cloud.
Obtaining of funding: W.E. Dismukes.
Administrative, technical, or logistic support: G.A. Cloud, R. Hafner, C.A. Kauffman, W.E. Dismukes.
Collection and assembly of data: G.A. Cloud, D.M. Bamberger.
In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B.
To compare amphotericin B with liposomal amphotericin B for induction therapy of moderate to severe disseminated histoplasmosis in patients with AIDS.
Randomized, double-blind, multicenter clinical trial.
21 sites of the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
81 patients with AIDS and moderate to severe disseminated histoplasmosis.
Clinical success, conversion of baseline blood cultures to negative, and acute toxicities that necessitated discontinuation of treatment.
Clinical success was achieved in 14 of 22 patients (64%) treated with amphotericin B compared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage points [95% CI, 1 to 52 percentage points]). Culture conversion rates were similar. Three patients treated with amphotericin B and one treated with liposomal amphotericin B died during induction (P = 0.04). Infusion-related side effects were greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002). Nephrotoxicity occurred in 37% of patients treated with amphotericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003).
Liposomal amphotericin B seems to be a less toxic alternative to amphotericin B and is associated with improved survival.
*For a list of study investigators and numbers of patients enrolled, see Appendix.
Amphotericin B is the preferred initial treatment for moderate to severe disseminated histoplasmosis. Because amphotericin B has many serious side effects, alternative treatments are needed.
This double-blind, multicenter trial compared liposomal amphotericin B with regular amphotericin B in patients with disseminated histoplasmosis and AIDS. Liposomal amphotericin B had a higher treatment response (88% vs. 64%) and lower mortality rates (2% vs. 13%). It also had fewer infusion-related side effects (25% vs. 63%) and less nephrotoxicity (9% vs. 37%).
Although expensive, liposomal amphotericin B is better than regular amphotericin B for treating severe disseminated histoplasmosis.
Flow of patients through the study.
Table. Characteristics of Patients with Progressive Disseminated Histoplasmosis and AIDS, according to Treatment Group
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS. Ann Intern Med. 2002;137:105–109. doi: 10.7326/0003-4819-137-2-200207160-00008
Download citation file:
Published: Ann Intern Med. 2002;137(2):105-109.
HIV, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only